Egypt’s pharmaceutical market have made a 24 percent growth in sales, reaching around 51.59 billion Egyptian pounds ($2.9 billion) in 2017, according to a recent report.
Earlier, sales dropped by 8.8 percent, registering 2.067 billion unit operations during 2016, IMS added.
“20 pharmaceutical firms captured 62.6 percent of the sector’s sales in Egypt during last year,” U.S. IMS Health Company said in a report sent to Amwal Al Ghad on Saturday.
These firms included Novartis, GlaxoSmithKline, Pharco, Sanofi, Amoun Pharmaceutical, Eipico, Eva Pharma, Hikma Pharmaceuticals, and Medical Union Pharmaceuticals, the report showed.
In addition, Multi Apex Pharma (MAP), Global Napi, Marcyrl Pharmaceutical Industries, AstraZeneca, and Abbott as well as Merck and Co., MSD, Servier Egypt, SEDICO Pharmaceutical, and Bayer were also in the list.
In December 2017, sales increased by 11.6 percent to around 4.9 billion pounds compared to the same period last year.